Anteris Technologies (ASX:$AVR) equity raising update

Anteris Technologies Ltd (ASX:AVR) provided an update on its equity raising, with a capital raise of $40 million through the issue of two million new ordinary shares at $20 per share. The funds will be utilized for preparation for the FDA Pivotal trial of the Company's DurAVRTM THV for treating severe aortic stenosis, continued Valve-in-Valve trials, and general working capital expenses.

Executive Commentary on Equity Raising Update

The funds raised through the equity raising will play a crucial role in advancing our innovative medical devices, particularly in preparing for the FDA Pivotal trial of our DurAVRTM THV for treating severe aortic stenosis. Additionally, the continued Valve-in-Valve trials and general working capital expenses are essential for the progress of our transformative solutions to structural heart disease patients.

Summary of Anteris Technologies (ASX:AVR) Equity Raising Update

Anteris Technologies Ltd (ASX:AVR) has successfully raised $40 million through the issue of two million new ordinary shares at $20 per share. The funds will be used for the preparation of the FDA Pivotal trial of the Company's DurAVRTM THV for treating severe aortic stenosis, continued Valve-in-Valve trials, and general working capital expenses. This equity raising demonstrates the company's commitment to advancing innovative medical devices and delivering clinically superior solutions for significant unmet clinical needs in the structural heart market.